Organization
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
6 abstracts
Abstract
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.Org: Merck & Co., Inc., Gustave Roussy Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yale University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Institute of Cancer Research, London, United Kingdom, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, Centre For Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom, Department of Oncology & Metabolism, University of Sheffield and Department of Oncology, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, United Kingdom,
Abstract
CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials.Org: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, The Institute of Cancer Research, ICR-CTSU, Liverpool Hospital Anatomical Pathology, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust,